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ABSTRACT: The P300/CBP-associated factor plays a central role in retroviral
infection and cancer development, and the C-terminal bromodomain provides an
opportunity for selective targeting. Here, we report several new classes of acetyl-lysine
mimetic ligands ranging from mM to low micromolar aﬃnity that were identiﬁed using
fragment screening approaches. The binding modes of the most attractive fragments
were determined using high resolution crystal structures providing chemical starting
points and structural models for the development of potent and selective PCAF
inhibitors.
■ INTRODUCTION
Bromodomains are epigenetic readers that speciﬁcally recognize
acetyl-lysine (Kac) marks on proteins. Targeting this protein
interaction module with small molecules has recently emerged
as a potential therapeutic strategy for the treatment of several
diseases including cancer and inﬂammation.1,2 To date, most
inhibitor development eﬀorts have been focused on the BET
family of bromodomain proteins for which several inhibitors
have now entered clinical testing. Bromodomains have good
predicted druggability,3 and selective chemical tool compounds
have been developed even for less attractive binding sites that
possess open or highly charged acetyl-lysine binding pockets
such as BAZ24,5 and ATAD2.6 In addition, potent inhibitors
have been developed for highly druggable bromodomains
present in BRPF,7,8 CBP,9 and BRD9.10 Interestingly, several
recent inhibitor development projects have highlighted the
success of fragment-based approaches identifying inhibitors, in
particular for poorly druggable bromodomains.5,6,8,11,12
P300/CBP-associated factor (PCAF, also known as histone
acetyltransferase KAT2B) is a multidomain protein that harbors
an acetyltransferase (HAT) and E3 ubiquitin ligase domains as
well as a C-terminal bromodomain that may associate with the
HATs P300 and CBP.13−15 While the roles of the
acetyltransferase and the E3 ubiquitin ligase activities have
been shown to be required for cell proliferation and
apoptosis,14−18 little is known about the regulatory function
of the PCAF bromodomain in cellular processes. Selective
inhibitors, so-called chemical probes, would therefore be
interesting reagents to unravel the functions of the PCAF
bromodomain and to assess its therapeutic potential as a
targeting site for drug development.
An important role of the PCAF acetyl-lysine recognition
module has already been demonstrated for the replication of
AIDS viruses. The PCAF bromodomain targets the HIV TAT
protein acetylated at K50, an essential association that activates
HIV-1 transcription and promotes the integrated proviral
replication.19,20 Development of PCAF bromo-domain inhib-
itors has therefore been proposed as a potential strategy for the
treatment of AIDS,19,20 and this strategy has been conﬁrmed by
early N1-aryl-propane-1,3-diamine-based compounds that have
been shown to prevent PCAF/TAT association.21
This compound class has recently been followed up by the
development of a series of 2-(3-aminopropylamino) pyridine 1-
oxide derivatives that however did not lead to improvement of
the micromolar potency of current PCAF bromodomain
inhibitors.22 This prompted us to identify more diverse
chemical starting points using fragment screening by thermal
shifts assays and NMR as well as structure-based approaches.
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■ RESULTS AND DISCUSSION
To extend structural knowledge from our previous apo crystal
structure,23 we initially determined the crystal structure of the
PCAF-acetyl-lysine complex to provide insights into acetyl-
lysine recognition. The binding mode of the acetyl-lysine in
PCAF strongly resembled that observed in other bromodo-
mains with the Kac carbonyl forming two canonical hydrogen
bonds to a conserved N803 and a conserved water molecule.
This water is part of a conserved intricate network of structural
waters located at the bottom of the pocket that bridge
interaction with the ZA loop Y760 and the backbone carbonyl
of E750 (Figure 1a). Despite sharing the conserved
interactions, the Kac binding groove in PCAF was fenced on
one side by the bulky residue Y809, resulting in a tight and
restricted pocket (Figure 1b). Large aromatic residues in this
position are not common for human bromodomains, present in
less than a third of proteins in the family.23
Another interesting structural feature was the extension of
the binding pocket by a shelf created by the ZA loop harboring
a mixture of hydrophobic and polar surface residues (Figure
1b). The wide ZA-loop pocket poses a challenge for inhibitor
development. However, recently the development of Baz2
inhibitors demonstrated that such large binding pockets can be
eﬃciently occupied for instance by aromatic ring systems of the
BAZ2-ICR probe that are aligned by intramolecular aromatic π-
stacking.4
The low aﬃnities of the previously developed compounds
prompted us to search for other Kac mimetics that would be
compatible with the constraint nature of the central PCAF
pocket. We employed diﬀerent techniques to screen two
fragment libraries. In one set of experiments, we used a thermal
stability shift assay to screen a small fragment set at 1 mM and
identiﬁed several fragments that resulted in positive melting
temperature (Tm) shifts in the range of ∼1−2 °C (Figure 2).
These hits were chemically diverse and contained diﬀerent
potential Kac mimetic scaﬀolds. The highest Tm shifts were
recorded for 1-methylquinolin-2(1H)-one) (1, BR004), 1H-
indole-5-carboxamide (2, BR005), 2-methylisoindolin-1-one (3,
BR013), 4-methoxybenzo[d]isoxazol-3-amine (4, MB360), 2,3-
dihydrobenzo[b][1,4]dioxine-5-carboxamide (5, MB364), and
(4-(1,2,3-thiadiazol-4-yl)phenyl)methanamine (7, MB093),
most of which comprised known Kac mimetic scaﬀolds. In
parallel, we used target immobilized NMR screening (TINS) to
screen a diverse collection of approximately 950 commercially
available fragments.24 We ﬁrst conﬁrmed that binding of Kac to
immobilized PCAF could be observed in 2% DMSO
(Supporting Information, Figure S1). Subsequently mixtures
of fragments were screened with a maximum of four
compounds per mix such that the DMSO concentration was
never more than 2%. Consistent with earlier predictions, we
observed a TINS proﬁle indicating that PCAF is highly
ligandable (Figure 2c). On the basis of the proﬁle, 63 hits were
selected, a 6.6% hit rate. In contrast to TINS, binding of Kac to
immobilized PCAF in the presence of DMSO could not be
detected by SPR. Consequently, only those hits that were
readily soluble in an aqueous buﬀer were orthogonally validated
by SPR. The binding of 17 hits could be fully characterized by
SPR, and three were selected for structural studies based on
novel features (Supporting Information, Figure S2 and Table
S1). These fragments (9, 10, and 11) also resulted in
substantial Tm shifts (Figure 2).
Figure 1. Structure of PCAF−Kac complex (PDB code 5fe0). (a)
Detailed interactions between the bound acetyl-lysine (Kac, shown in
yellow stick) and the PCAF bromodomain. Water molecules are
shown as pink spheres. (b) Electrostatic surface representation reveals
a tight central Kac pocket that is extended by wide cavities lined by the
ZA and BC loop regions. Inset shown |2Fo| − |Fc| omitted electron
density map for the bound Kac.
Figure 2. Fragments containing Kac mimetics identiﬁed as potential
binders for PCAF bromodomain. Chemical structures of the identiﬁed
fragments are shown in (a) together with average Tm shifts (±SEM)
using triplicate experimental data listed in (b). (c) TINS proﬁle. The
T/R ratio of each compound screened was calculated as a height
weighted average of the ratio of the peak amplitude of each NMR
resonance in the presence of PCAF over that in the presence of the
reference protein. The T/R ratios were then binned, and the frequency
is plotted above. The asymmetry and tailing to the left (i.e., a large
number of compounds displaying preferential binding to PCAF) are
indicative of high ligandability of PCAF. The vertical red-dashed line
indicates the cutoﬀ for deﬁnition of hits. Data of TINS hits are
compiled in Supporting Information, Table S1.
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We next attempted to verify the binding modes of the
identiﬁed fragments and successfully determined the complex
crystal structures for seven Kac mimetic fragments. As expected
from their chemical structure, all of these fragments occupied
the Kac binding site through groups that mimicked the
hydrogen bond interaction of acetyl-lysine. Because the co-
crystallized compounds were small, the contacts with the
bromodomain were limited only to the canonical hydrogen
bond with N803 and the typical water-mediated contact with
Y760 (Figure 3a). However, additional interactions were also
observed for Fr11, of which the 1-ethanol decoration was
oriented toward the open ZA cavity and formed both direct and
water-mediated hydrogen bonds to the backbones of the ZA
loop V752 and P751. Superimposition of all structures revealed
that the co-crystallized fragments ﬁt tightly into the narrow Kac
pocket, and most fragments formed aromatic interactions with
Y809 that lines the central acetyl-lysine binding groove of the
PCAF bromomdomain (Figure 3b). No signiﬁcant structural
alterations were observed when comparing all complexes,
suggesting that the PCAF bromodomain contains a rigid acetyl-
lysine binding pocket. Some Kac mimetic groups of the
identiﬁed fragments were not speciﬁc for PCAF and have been
previously shown to bind to other bromodomains, for example,
1 also interacts with ATAD211 and the isoxazole 8 with BRD4
and CREBBP25 with highly conserved binding modes.
With the success in identifying the Kac mimetic fragments
and obtaining the complex structures, we next expanded the
ligand series to more decorated compounds by choosing two
diverse scaﬀolds (Figure 4a). Two compounds, CPD1 (12) (N-
(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)acetamide) and
CPD2 (13) (N-(1,4-dimethyl-2-oxo-1,2-dihydroquinolin-7-yl)-
methanesulfonam), were derivatives based on fragment hit 1
containing an additional 4-methyl group and two diﬀerent
decorations at the seventh position, either with N-linked
acetamide or sulfonamide. A third inhibitor, CPD3 (14) (N-
methyl-5-(2-oxo-2-(phenylamino)ethoxy)-2-((tetrahydro-2H-
pyran-4-yl)oxy)benzamide), contained instead a benzene core
harboring an acetamide extension, a Kac mimetic group
resembling fragment 1. In addition, this latter compound was
also further decorated by tetrahydropyran and N-phenyl-
acetamide linked to the benzene ring via an ethoxy linkage at
the ortho and meta positions relative to the acetamide group,
respectively.
The binding of these three compounds was initially
conﬁrmed by DSF with 12 and 13, showing a similar degree
of stabilization with ΔTm shifts of ∼2.6−2.9 °C at 1 mM
concentration (Figure 4b). Because of signal interference, 14
was used at half the concentration of the others but nonetheless
produced a similar ΔTm shift of ∼3.3 °C. As expected, the
increase of the ΔTm shift values of these three ligands suggested
stronger binding to PCAF bromodomain. We used isothermal
titration calorimetry (ITC) to determine binding aﬃnities in
solution.
In agreement with the DSF results, the measured Kd of 13
was observed to be ∼21 μM, which was 3-fold higher than that
of the more decorated 14 (Kd of ∼7 μM) (Figure 4c). The
increase in the aﬃnity of the latter was due to signiﬁcantly
larger negative binding enthalpy, suggesting more favorable
polar interaction of this inhibitor. However, the ligand
eﬃciency (LE) decreased to 0.24 for 14 compared to LE of
0.34 for 13. To gain insight into the selectivity of the most
potent fragment hits, we performed a temperature shift screen
using a panel of 48 recombinant bromodomains (Supporting
Information, Figure S3). This selectivity screen revealed strong
interaction of 14 to bromodomains present in CECR2 (7.1
°C), BRD7 (6.5 °C), suggesting that this fragment can also be
optimized targeting other bromodomains. 12 and 13 were also
screened using developed Alphascreen assays. At 25 μM, both
inhibitors showed strong inhibition for BRD9 (Supporting
Information, Table S2). This is not surprising because 1-
Figure 3. Structures of PCAF in complexes with the identiﬁed Kac
mimetic fragments. (a) Detailed interactions between the bound
fragments (yellow stick) within the PCAF Kac binding site. The
conserved water molecules at the bottom of the pocket are shown in
pink spheres, and an additional water molecule involving in additional
water-mediated interactions observed in the complex with 11 is
highlighted by magenta sphere. (b) Superimposition of the bound
fragments and Kac revealed canonical acetyl-lysine mimetic binding
modes and no signiﬁcant conformational changes upon inhibitor
binding within the pocket. Coordinates have been deposited under
accession codes: 5fe1, 5fe2, 5fe3, 5fe4, 5fe6, 5fe7, and 5fe5.
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methylquinoline-2-ones have been developed into highly
speciﬁc BRD9 inhibitors.10
The crystal structures of the ligand−PCAF complex allowed
us to evaluate the interactions of the introduced decorations.
All compounds could be unambiguously positioned based on
the well-deﬁned electron density map (Figure 5). As expected
in complexes with 12 and 13, the 1-methylquinoline-2-one
group occupied the Kac binding groove and formed similar
canonical interactions as observed in the PCAF complex with 1,
while the decoration of both compounds oriented toward the
ZA pockets. However, no contact between the 12 acetamide
and protein was observed. In contrast, the 13 N-linked
sulfonamide was observed to replace a water molecule that
bridged interactions between E756 and K753 in the Kac
complex (Figure 1a), enabling the formation of two direct
hydrogen bonds to these two residues as well as a water-
mediated contact to the carbonyl backbone of W746 (Figure
5). Interestingly, a sulfonamide at this analogous position also
engaged within the Kac site of BAZ2B in the GSK2801
inhibitor complex.5
The binding mode of 14 was slightly diﬀerent potentially due
to its larger decorations and its diﬀerent acetyl-lysine mimetic
moiety (Figure 5). The acetamide interacted with PCAF in a
typical Kac mimetic manner, with the benzene core stacking
against the Y809 in a similar fashion observed also for the other
fragments. The tetrahydropyran expanded into the open ZA
pocket, while the N-phenylacetamide extension occupied the
BC pocket with the phenyl ring located above N803 and
oriented perpendicularly to Y802 and P804 within a distance
for π-stacking. However, no hydrogen bond contact was formed
between these substitutions and PCAF. Considering its aﬃnity,
such limited interactions were rather surprising when compared
to the binding mode of the weaker 13, of which the extended
group engaged in more hydrogen bond interactions. We
hypothesize therefore that 14 may gain its increased binding
potency through a larger contact surface. Hence, an extension
of the Kac-mimetic fragments resulted in improved binding
aﬃnities despite the lack of direct polar interaction with the
protein. In addition, the large surrounding space adjacent to the
ZA and BC loops provides few spatial constraints, enabling the
binding of diverse chemical moieties, albeit with little shape
complementarity. It is likely that elongated, ﬂexible, and
uncharged substituents that could span the interface as well
as engage a few interactions may be beneﬁcial for increasing
ligand potency through targeting the ZA and BC pockets in the
PCAF bromodomain.
Figure 4. Compounds identiﬁed as PCAF binders. (a) Chemical structures of three in-house available compounds that contain the fragment-related
Kac mimetic scaﬀolds. (b) Average Tm shift values from triplicate experiments for the selected compounds. (c) ITC binding data for the interactions
between 13 and 14 with PCAF with the isotherms of raw titration heat shown on the top and the normalized binding heat with the single-site ﬁtting
(red line) shown at the bottom. The thermodynamic parameters including equilibrium binding constants are the average from two repeats.
Figure 5. Crystal structures of PCAF in complexes with 12, 13, and 14. Detailed interactions between the bound compounds with the PCAF
bromodomain are shown. The conserved water at the bottom of the pocket is displayed in pink spheres, while an additional water molecule involving
in contact between the 13 and protein is shown in magenta sphere. Insets show omitted electron density map for the bound ligands. Coordinates
have been deposited under accession codes: 5fe8, 5fe9, and 5fdz, respectively.
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■ CONCLUSION
The fragment-based approach coupled with structural informa-
tion presented here oﬀers a platform expanding the knowledge
on PCAF Kac-mimetic scaﬀolds and binding modes to aid
development of potent and selective PCAF bromodomain
inhibitors. The structural models provide valuable data for the
rational design of inhibitors to the rigid and poorly enclosed
PCAF Kac binding pocket. Comparison of inhibitor binding
modes highlights the importance of aromatic interactions with
Y809 and provides several diverse acetyl-lysine mimetic
chemotypes. These chemotypes may serve as attractive starting
points for inhibitor development eﬀorts targeting this
interesting bromodomain. All fragments that were cocrystal-
lized formed an acetyl-lysine mimetic hydrogen bond to N803.
Thus, for future development of these fragments into more
potent hits the fragment need to be grown rather than linked in
order to increase potency.
■ EXPERIMENTAL SECTION
Recombinant Protein Production. The PCAF bromodomain
(aa 715−831) containing an N-terminal His6-tag was recombinantly
expressed in Escherichia coli Rosetta. The protein was initially puriﬁed
by Ni2+-aﬃnity chromatography and subsequently cleaved the tag with
TEV protease. The cleaved protein was further puriﬁed using size
exclusion chromatography and stored in 25 mM HEPES, pH 7.5, 150
mM NaCl, and 0.5 mM TCEP.
Identiﬁed Fragments and Compounds. Fragments were
purchased from chemical vendors and were at least 95% pure
according vendor speciﬁcations. The purity and correct structure of
each compound was validated by NMR. The purity of the synthesized
compounds 12, 13, and 14 was assessed by analytical HPLC using an
Agilent 1100 equipped with photodiode array detector (DAD),
quaternary gradient pump, and micro plate sampler (Agilent 220).
Separation was performed upon Centurysil C18-AQ + 5 μm, 50 mm ×
4.6 mm (Johnson). The ﬂow rate of the mobile phase was kept at 3.5
mL/min. Mobile phases B and C were acetonitrile with 0.35%
CF3CO2H and water with 0.35% CF3CO2H, respectively. The gradient
conditions were as follows: 0−0.5 min 1% B and 99% C, 3.7 min 90%
B and 10% C, 5 min 99% B and 1% C. The injection volume was 10
μL. 12 and 13 were ≥90% pure by HPLC at 254 nm and ≥99% by
evaporative light scattering detection (ELSD). 14 was ≥99% pure by
both methods.
Thermal Stability Assays. The protein at 2 μM in 10 mM
HEPES, pH 7.5 and 250 mM NaCl was mixed with the fragments/
compounds at 1 mM concentration (unless stated). The assays, data
evaluation, and melting temperature (Tm) calculation were performed
using a Real-Time PCR Mx3005p machine (Stratagene) with the
protocols described previously.26
Isothermal Calorimetry. All isothermal calorimetry (ITC)
experiments were carried out on NanoITC (TA Instruments) at 15
°C in the buﬀer containing 25 mM HEPES, pH 7.5, 150 mM NaCl,
and 0.5 mM TCEP. Titration was performed by injecting PCAF (250
μM) into the reaction cell containing the compounds (15−20 μM).
The corrected data of the integrated heat of titration were ﬁtted to an
independent single binding site model based on the manufactor
protocol, from which the thermodynamics parameters (ΔH and TΔS),
equilibrium association and dissociation constants (Ka and KD), and
stoichiometry (n) were calculated. All experiments were repeated
twice.
SPR. Recombinant PCAF was biotinylated on the N-terminal AVI
tag in vivo. Puriﬁed, biotinylated PCAF was captured onto a
NeutraAvidin-coated CM5 sensor chip surface in 20 mM sodium
phosphate pH7.5, 150 mM NaCl, 2 mM DTT, and 0.05% P20 Tween.
This buﬀer was subsequently used for all studies. The immobilization
level was 10150 RU. All SPR experiments were performed using a
Biacore T200 instrument at 20 °C. Fragment hits from TINS were
directly solubilized in the running buﬀer. Each fragment was titrated at
six diﬀerent concentrations for KD determination. An acetyl-Lys 16
peptide derived from H4 was used to monitor the ligand binding
capacity of the immobilized PCAF bromodomain at regular intervals.
Crystallization and Structure Determination. Apo crystals of
PCAF (∼14−18 mg/mL) were obtained using the vapor diﬀusion
method at 4 °C and either single-PEG-based (21−35% PEG 3350, 0.1
M Bis-Tris pH 5.5−7.0) or PEG-smear-based (21−40% medium-
molecular-weight PEG smears buﬀered either with 0.1 M Bis-Tris pH
6.0−7.5 or 0.1 M Tris pH 7.5−8.8)27 reservoir solutions. To produce
the PCAF−ligand complex crystals, soaking was performed using the
mother liquor supplemented with the fragments/compounds at ∼10−
20 mM concentration and 20% ethylene glycol. Diﬀraction data were
collected either in-house or at the Diamond Light Source. Initial
structure solution was achieved using molecular replacement with
Phaser28 from CCP4 suite29 and the published coordinates of PCAF.23
Manual model building alternated with reﬁnement were performed in
COOT30 and Refmac,31 respectively. Data collection and reﬁnement
statistics are summarized in Supporting Information, Table S3.
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